30 August 2016

New clinical data on RPL554 to be presented at the 2016 ERS International Congress

Detailed data from Phase 2a "add-on" trial as "LATE-BREAKING abstract"

30 August 2016, Cardiff – Verona Pharma plc (AIM: VRP.L), the drug development company focused on first-in-class medicines to treat respiratory diseases, today announces that it will present three abstracts at the European Respiratory Society (ERS) 2016 International Congress in London, UK between 3-7 September. The abstracts will cover clinical data related to the Company's lead drug, RPL554, a novel inhaled dual PDE3/PDE4 inhibitor with both bronchodilator and anti-inflammatory properties. RPL554 is currently in development as a nebulised maintenance treatment for chronic obstructive pulmonary disease (COPD) patients with moderate to severe disease and as a treatment for acute exacerbations in COPD patients in a hospital or home-care setting.

Detailed results from the Company's Phase 2a "add-on" trial, where RPL554 produced a statistically and clinically significant additional bronchodilation on top of standard of care bronchodilators in COPD patients, will be presented for the first time in an oral presentation, by Professor Dave Singh from the Medicines Evaluation Unit, University of Manchester, during a late-breaker session on Monday, 5 September 2016, at 11:00 in Room C.

All three abstracts presented at ERS support Verona Pharma's view that RPL554 could become an important, novel and complementary inhaled medicine for the treatment of respiratory diseases such as COPD, asthma and cystic fibrosis. In summary, the detailed data supports previously announced analysis of headline data which identified:

- Profound and sustained bronchodilation in healthy volunteers, COPD patients and asthmatics;
- Comparable bronchodilation to high dose nebulised salbutamol (a standard of care treatment) in asthmatics with fewer systemic effects; and
- Statistically and clinically significant improvements in lung function when administered as "add-on" treatment to existing standard of care bronchodilators in COPD patients.

All abstracts and details on timings can be accessed through the ERS website:erscongress.org/

The title, timing and location of the abstract presentations are as follows:

Abstract Number:
750050

Authors:
D. Singh, K.H. Abbott-Banner, K. Newman

Title:
LATE-BREAKING ABSTRACT: The novel inhaled dual PDE3/4 Inhibitor, RPL554, produces significant additional improvements in lung function when administered on top of existing standard of care in COPD patients

Day/Date:
MONDAY, September 5, 2016

Location:
Room C

Time:
10:45 - 12:45

Session:
Late-breaking topics in airways disease

Session Type:
Oral Presentation

Abstract Number:
851700

Authors:
D. Singh, K.H. Abbott-Banner, K. Newman

Title:
RPL554, an inhaled PDE3/4 inhibitor, causes profound and sustained bronchodilation in healthy volunteers and COPD patients

Day/Date:
TUESDAY, September 6, 2016

Location:
T-21

Time:
12:50 - 14:40

Session:
Novel avenues in the treatment of COPD

Session Type:
Thematic Poster Session

Abstract Number:
853133

Authors:
L. Bjermer, J. Stewart, K. Abbott-Banner, K. Newman

Title:
RPL554, an inhaled PDE3/4 inhibitor, causes comparable bronchodilation to high dose nebulised salbutamol in asthmatics with fewer systemic effects

Day/Date:
WEDNESDAY, September 7, 2016

Location:
Room ICC Capital Suite 8.

Time:
8:30 - 10:30

Session:
Novel mechanisms and treatment modalities in asthma

Session Type:
Poster Discussion

-ENDS-

For further information please contact: Verona Pharma plc

Verona Pharma plc
Jan-Anders Karlsson, CEO

Tel: +44 (0)20 3283 4200
info@veronapharma.com

N+1 Singer (Nominated Adviser and UK Broker)
Aubrey Powell / James White
Tel: +44 (0)20 7496 3000

FTI Consulting
Simon Conway / Stephanie Cuthbert / Natalie Garland-Collins
Tel: +44 (0)20 3727 1000
veronapharma@fticonsulting.com

ICR, Inc. (US Media and Investor enquiries)
James Heins
Tel: +1 203-682-8251
James.Heins@icrinc.com

Stephanie Carrington
Tel. +1 646-277-1282
Stephanie.Carrington@icrinc.com

About Verona Pharma plc
Verona Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapeutics for the treatment of respiratory diseases with significant unmet medical needs. Verona Pharma's product candidate, RPL554, is a first-in-class, inhaled, dual inhibitor of the enzymes phosphodiesterase 3 and 4 that acts as both a bronchodilator and an anti-inflammatory agent in a single compound. In clinical trials, treatment with RPL554 has been observed to result in statistically significant improvements in lung function as compared to placebo and has shown clinically meaningful and statistically significant improvements in lung function when added to two commonly used bronchodilators as compared to either bronchodilator administered as a single agent. RPL554 has also shown anti-inflammatory effects and been well tolerated in clinical trials. Verona Pharma is developing RPL554 for the treatment of chronic obstructive pulmonary disease (COPD), cystic fibrosis, and potentially asthma.

Forward Looking Statements
This press release contains forward-looking statements. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements.

These forward-looking statements are based on management's current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from our expectations expressed or implied by the forward-looking statements, including, but not limited to, the development of DPI and MDI formulations of RPL554 and the potential for these formulations to increase the market opportunity for the product, if approved.

These and other important factors could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management's estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.
